Yisheng Us Biopharma

Parent

Yisheng US Biopharma, Inc established in Maryland, USA in 2009 is located in Gaithersburg within the Maryland's I-270 Biotech Corridor and is a subsidiary of YS Biopharma Co. Ltd. Its R&D activities are focusing on the research and development of novel, first-in-class, preventive and therapeutic vaccines and therapeutics to treat serious diseases and indications including viral infections (rabies, hepatitis B, influenza, shingles and Covid-19) and some cancers, which are based on the platform of its proprietary PIKA adjuvant immunomodulating technology. In accordance with its mission, the company has set up a team of domestic and oversea professionals with extensive experience in biotechnology, management and multidisciplinary scientists through partnerships with large pharmaceutical and major biotech companies. To see our capabilities statement, please copy and paste this web address: http://ysbiopharmus.com

PIKA immunomodulating technology, antiviral vaccines, antiviral therapeutics, anticancer therapeutics, PIKA recombinant COVID-19 vaccine, PIKA rabies vaccine, PIKA preventive, therapeutic hepatitis B vaccine, immuno-oncology biotherapeutics

Gaithersburg, MD
United States